Recursion (RXRX) CFO has 2,271 shares withheld for RSU taxes

Recursion Pharmaceuticals, Inc. (RXRX) Chief Financial Officer reported a routine share withholding related to equity compensation.

Rhea-AI Filing Summary

Recursion Pharmaceuticals, Inc. (RXRX) Chief Financial Officer reported a routine share withholding related to equity compensation. On 11/25/2025, 2,271 shares of Class A common stock were disposed of in a transaction coded "F" at a price of $4.03 per share. This code indicates shares were withheld by the company to cover tax withholding and remittance obligations arising from the net settlement of restricted stock units.

Following this transaction, the reporting officer beneficially owns 789,990 shares of Class A common stock in direct ownership. No new derivative securities transactions were reported in this filing.

Insider Trade Summary

Exercise Price or Tax Liability: 2,271 shares

Exercise Price or Tax Liability 1 txn

Insider Taylor Ben R

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Class A Common Stock	2,271	$4.03	$9K

Holdings After Transaction: Class A Common Stock — 789,990 shares (Direct)

Footnotes (1)

1. F1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Recursion Pharmaceuticals (RXRX) report in this Form 4 filing?

The filing reports that the Chief Financial Officer had 2,271 shares of Class A common stock withheld on 11/25/2025 to satisfy tax withholding obligations related to restricted stock units.

Who is the reporting person in this RXRX Form 4 and what is their role?

The reporting person is an officer of Recursion Pharmaceuticals, Inc., serving as the Chief Financial Officer.

How many Recursion Pharmaceuticals shares were involved in the reported transaction?

A total of 2,271 shares of Recursion Pharmaceuticals Class A common stock were disposed of through share withholding to cover taxes.

What was the price used for the RXRX share withholding transaction?

The shares were valued at $4.03 per share for the 2,271 share tax withholding transaction on 11/25/2025.

How many RXRX shares does the officer own after this Form 4 transaction?

After the transaction, the officer beneficially owns 789,990 shares of Recursion Pharmaceuticals Class A common stock in direct ownership.

What does transaction code "F" mean in this RXRX Form 4?

Transaction code "F" indicates shares were withheld by the issuer to satisfy tax withholding and remittance obligations from the net settlement of restricted stock units.

Were any derivative securities reported in this RXRX Form 4?

No. The section for derivative securities shows no acquisitions or dispositions reported in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/26/2025 - 05:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taylor Ben R

(Last) (First) (Middle)

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UT 84101

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	11/25/2025		F(1)		2,271	D	$4.03	789,990	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.

Remarks:

	/s/ Kyle Nelson, attorney-in-fact	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.